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Abstract
Background: Health-related quality of life (HRQOL) is an important outcome indicator for chronic disease, and
particularly in the absence of biological markers for illness, such as with irritable bowel syndrome (IBS). The aims
of this study were to develop and evaluate a new IBS-specific HRQOL instrument (IBS-HR-QOL).
Methods: This methodological study comprised three steps: conceptualization of the IBS-HR-QOL, item extraction and
establishment of content validity, and psychometric evaluation of the instrument with 267 IBS patients recruited from
four university hospitals.
Results: The content validity of the developed IBS-HR-QOL was assessed by 11 experts. Exploratory and confirmatory
factor analyses yielded four factors. The criterion and convergent validities of the IBS-HR-QOL were demonstrated using
the Short Form-36 and the Hospital Anxiety and Depression Scale, respectively. Known-groups validity was demonstrated
using a symptom-severity scale. The internal consistency reliability and test-retest reliability were satisfactory, with a
Cronbach’s alpha and intraclass correlation coefficient of 0.93 and 0.88, respectively.
Conclusions: The IBS-HR-QOL comprises a total of 16 items. The IBS-HR-QOL demonstrated good psychometric
properties. This instrument is easily comprehensible and short, rendering it feasible for use in clinical practice and
research.
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Background
Irritable bowel syndrome (IBS) is a functional gastrointes-
tinal disorder that is characterized by abdominal pain or
discomfort associated with altered bowel habits, with an
uncertain organic cause [1]. It is a common condition with
a global prevalence of 11.2 % [2], conferring a substantial
health-related economic burden upon society, and signifi-
cantly impairing the health-related quality of life
(HRQOL) at the individual level [3].
HRQOL is considered an important outcome indicator
for chronic disease or illness, since the traditional indicators
that are used in clinics (e.g., physical, physiological, or
biochemical indicators) cannot fully assess the impact of
disease or its treatment on patients [4]. Measurement of
HRQOL to evaluate and follow-up disease is of particular
importance in the case of illnesses for which there are cur-
rently no biological markers, such as IBS. In the clinical
management of IBS patients, an HRQOL assessment may
help health professionals to check responses to treatment,
facilitate communication with the patients or their families,
and deliver optimal care to the patients [5]. Therefore, the
American College of Gastroenterology has recommended
the routine assessment of HRQOL in IBS patients [1]. The
gastroenterology division of the United States Food and
Drug Administration has recommended evaluation of
HRQOL in clinical trials of IBS treatments [6].
There exist generic and disease-specific HRQOL in-
struments. Generic instruments can be used to assess
healthy populations or for comparisons with other dis-
ease populations, while disease-specific instruments are
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used to assess patients with a particular disease, since
they are more sensitive to the patients’ condition or con-
cerns [7]. Several IBS-specific HRQOL instruments have
been developed over the last 17 years: Irritable Bowel
Syndrome Quality of Life (IBSQOL) [8], Irritable Bowel
Syndrome-Quality of Life (IBS-QOL) [9], Irritable Bowel
Syndrome Health Related Quality of Life (IBS-HRQOL)
[10], IBS-36 [11], and IBS Impact Scale (IBS-IS) [12].
However, these existing instruments have some meth-
odological limitations. For example, all except the IBS-
QOL [8] were developed and tested using samples that
were too small. The structural validity of patient-
reported outcome instruments is usually evaluated using
exploratory factor analysis (EFA) and confirmatory factor
analysis (CFA); the former is used to identify underlying
factors or item reduction, while the latter is used to as-
sess the extent to which the factors proposed by the EFA
fit the data [13]. Although the underlying factors of the
IBS-QOL [9], IBS-IS [12], and IBS-HRQOL [10] were
assessed using EFA, the results were unclear and/or the
underlying factors were not subsequently evaluated
using CFA. Hence, these limitations may threaten the
findings of clinical trials or interventions in which these
instruments are used as an outcome parameter. The aims
of this study were to develop a new IBS-specific HRQOL
instrument (called IBS-HR-QOL), and to test the psycho-
metric properties of the instrument in patients with IBS.
Methods
Step 1: conceptualization
The fundamental consideration in the development of
an instrument is defining the concept that is to be mea-
sured. Although there is no universally accepted defin-
ition of HRQOL, the following attributes have been
widely agreed upon: a) HRQOL is subjective, and hence
it depends upon the individual’s perception of the impact
of his/her disease and its treatment on various aspects of
his/her health-related life, and b) HRQOL comprises
multidimensional constructs [14]. HRQOL has been de-
fined as “the assessment of the impact of disease and
treatment across the physical, psychological, social, and
somatic domains of functioning and well-being” [15].
Combining attributes and implication, the concept of
HRQOL being measured in the present study was
defined as the individual’s subjective perception of the
effects of IBS on various aspects of his/her the health-
related life, such as somatic, dietary, emotional, and
social aspects.
Step 2: item extraction and content validity
A pool of 48 attributes was derived from literature re-
views on qualitative and quantitative studies, and from
discussions with 4 clinicians. Each attribute was formu-
lated into an item. A 5-point Likert scale was used as a
response format for the items, ranging from 0 (“not at
all”) to 4 (“very much”); this is the most frequently used
response format in survey questionnaires [16]. The con-
tent validity of the preliminary questionnaire was evalu-
ated by a panel of 11 experts (7 gastroenterologists and 4
experts on concept analysis). A content validity ratio
(CVR) was calculated for each item. A minimum CVR of
0.59 was considered as a threshold value at p < 0.05 [17].
Step 3: psychometric evaluation
Sample and data collection procedures
A convenience sample of 267 patients with IBS was
recruited from outpatient clinics at 4 university hospitals
in South Korea (Table 1). The inclusion criteria were be-
ing aged at least 20 years, articulate in Korean, diag-
nosed with IBS by gastroenterologists based on the











≥ 70 18 (6.7)
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Missing value 3 (1.1)
Education
Elementary school 14 (5.3)
Middle school 22 (8.2)
High school 71 (26.6)
College and above 157 (58.8)
Other 1 (0.4)






IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS; IBS-M,
mixed-symptom IBS; IBS-U, IBS subtype unknown
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Rome III criteria [18], and an absence of abnormal re-
sults on a colonoscopic examination.
Potential patients who met the inclusion criteria were
recruited by research assistants at outpatient clinics. The
research assistants met those potential patients who
agreed to participate in this study in a small private
room, and informed them about the purpose of the
study, the confidentiality of their data, and their right to
withdraw from the study at any time. They were then
asked to sign on a written consent form. Thereafter the
patients were provided with a package of questionnaires
and asked to complete them in the private room.
The test–retest reliability of an instrument can be
assessed by applying it at least twice to the same individ-
uals with an interval of 1–2 weeks [9, 11]. Therefore, some
of the participants in this study were required to complete
the IBS-HR-QOL instrument twice, with a 1-week inter-
val. In total, 59 of the patients agreed to provide repeat re-
sponses to the IBS-HR-QOL questionnaire. These
patients were given an envelope with a returning address
and a stamp, in which an uncompleted IBS-HR-QOL
questionnaire was enclosed, for the assessment of test–re-
test reliability. They were asked to take the envelope
home, complete the IBS-HR-QOL 1 week later, and then
post the return envelope to the researchers.
Ethical considerations
This study was approved by the institutional review
boards of the hospitals at which the participants were re-
cruited (IRB reference numbers BD2013-094, SIRB-
00200-2-002, GBIRB2013-251, and KUGH13183-001).
Measures
Short Form-36 (SF-36)
The SF-36 was used to test the criterion validity of the
IBS-HR-QOL. The SF-36 measures generic HRQOL [19],
and comprises eight subscales (physical functioning, role
physical, bodily pain, role emotional, vitality, mental
health, social functioning, and general health), with higher
scores indicating a better HRQOL. The reliability and val-
idity of the Korean version of the SF-36 have been demon-
strated in 2,511 Koreans [20]. In the present study it was
hypothesized that the IBS-HR-QOL would be moderately
positively correlated with the SF-36, since a disease-
specific HRQOL is generally known to be moderately cor-
related with generic HRQOL instruments [21].
IBS Symptom-Severity Scale (IBS-SSS)
The IBS-SSS, which measures lower-gastrointestinal
symptom severity, was used to assess known-groups val-
idity [22]. The IBS-SSS consists of five items, and the
total score ranges from 0 to 500. Participants with scores
of <175, 175–300, and >300 were classified as mild,
moderate, and severe groups, respectively. In this study,
it was hypothesized that the IBS-HR-QOL score would
be higher for a more severe IBS-SSS classification [9,
23].
Hospital Anxiety and Depression Scale (HADS)
The HADS, which measures anxiety and depression in
people with illness, was applied in this study [24]. HADS
scores are summed, with higher scores indicating a higher
level of anxiety and depression. The HADS has previously
been demonstrated to have satisfactory reliability and
validity in a Korean population [25]. A prior hypothesis
for convergent validity in the present study was that there
would be a moderate correlation between the HADS and
IBS-HR-QOL scores [12].
Data analysis
The Statistical Package for the Social Sciences (version 20)
and AMOS were used to analyze the data. A zero-order
correlation matrix was computed to identify uncorrelated
or redundant items. If the interitem correlation coefficient
was <0.3 or >0.8, the item was eliminated [26].
Regarding structural validity, the required sample size
was at least seven times the number of items, but with
100 individuals as an absolute minimum [27]. The sample
size included in this study met this requirement. Bartlett’s
test of sphericity and the Kaiser-Mayer-Olkin measure of
sampling adequacy (KMO) were computed to justify
undertaking a factor analysis. EFA was conducted to re-
duce the items and explore their underlying structure,
using principal-components analysis with varimax rota-
tion. Factors with an eigenvalue of >1 were extracted. The
criterion for factor loadings was set at ≥0.60 [28].
The fit of the underlying structure to the observed data
were confirmed through CFA using a maximum-
likelihood method. The CFA model fit was assessed using
multiple fit indices and their acceptable criteria: the
normed χ2 [the ratio of χ2/df < 3], goodness-of-fit index
(GFI > 0.9), standardized root mean square residual
(SRMR < 0.05), root-mean-square error of approximation
(RMSEA < 0.08), comparative fit index (CFI > 0.90), and
normed fit index (NFI > 0.90) [29, 30].
As an ancillary test of the structural validity, multigroup
CFA (MGCFA) was performed to determine whether or
not the proposed factor model was invariant across the
IBS-subtype groups. First, a configure model (Model 1)
was used to assess whether or not the factor structure was
similar across the groups. Factor-loading invariance
(Model 2: by constraining factor loadings to be the same
across groups), covariance invariance (Model 3: by
constraining factor loadings and covariance), and error
variance invariance (Model 4: by constraining factor load-
ings, covariance, and error variance) were then also used.
The MGCFA assessment was achieved with RMSEA
(<0.08) and χ2 difference (Δχ2). If the Δχ2 of the sequential
Lee et al. Health and Quality of Life Outcomes  (2016) 14:22 Page 3 of 9
comparisons between the models was not significant, the
invariance across groups was satisfied [29].
Criterion and convergent validities were examined using
the SF-36 and HADS, respectively, with Pearson’s correl-
ation. The known-groups validity of the IBS-HR-QOL ac-
cording to the IBS-SSS group was tested using ANOVA or
Welch’s test (the latter was used when the homogeneity of
variances among three groups was violated). Cohen’s ef-
fect size was computed to assess the magnitude of known-
groups validity [4, 31, 32].
Internal consistency reliability was tested using cor-
rected item-total correlations and Cronbach’s alpha; a
Cronbach’s alpha value of 0.70–0.95 was acceptable for
internal consistency [27]. Test–retest reliability was
examined using the intraclass correlation coefficient
(ICC); the threshold ICC value for acceptable test–re-
test reliability was set at ≥0.70 [27].
Results
Content validity
Of the 48 items, 29 satisfied the threshold CVR value of
>0.59. The remaining 18 items were deleted. The experts
reported that three items were difficult to understand and
that two items were ambiguous to answer. Those three
items were thus modified so that they were clearer and
more comprehensible.
Missing values and correlation matrix
The score for each item ranged from 1.60 ± 1.28 to 3.53 ±
0.95. The rate of missing values for each item ranged from
0 to 1.5 %. The missing values were completed using
expectation-maximization. In the 29 × 29 correlation
matrix, one item (“sexual relationship”) was not signifi-
cantly correlated with more than half of the other items,
and was thus eliminated.
Structural validity
Bartlett’s sphericity was significant (χ2 = 5424.05, p < 0.001).
The KMO was superb, at 0.94, implying that a factor ana-
lysis could be used to identify factors [33]. The initial EFA
extracted a four-factor solution, which accounted for
64.47 % of the total variance. Twelve items did not load
onto any of the four factors at the criterion value. After ex-
cluding these 12 items, consecutive factor analysis again ex-
tracted a 4-factor solution, but the explained variance had
increased to 72.93 %. All 16 items meaningfully loaded onto
1 of the 4 factors. No item loaded onto cross factors above
the criterion value of 0.6 (Table 2). The four were named as
“bowel function,” “emotions,” “concerns about social activ-
ity,” and “consideration of foods.”
CFA was computed for the fit of the extracted four-
factor model to the data. The normed χ2 = 2.97, SRMR
= 0.05, GFI = 0.88, RMSEA = 0.08 (90 % CI = 0.07–0.09),
NFI = 0.89, IFI = 0.93, and CFI = 0.93. The GFI, RMSEA,
and NFI were either not satisfied or did not reach the
criterion cutoff. Therefore, explorative post-hoc inspec-
tion of model misspecification was carried out using
modification indices (MIs). It was found that the error
terms between items 3 and 4 exhibited a high MI
(32.42). After fitting the item error covariance, χ2 de-
creased to 250.59 (Δχ2 = 40.76, p < 0.001), implying sig-
nificant improvement of the model. The modified model
fit indices were also improved and fitted the data well:
normed χ2 = 2.97, SRMR = 0.05, GFI = 0.90, RMSEA =
0.07 (90 % CI = 0.06–0.08), NFI = 0.91, IFI = 0.94, and
CFI = 0.94. The item loadings to the factors ranged from
0.64 to 0.87 (Fig. 1).
Regarding the ancillary analysis for structural validity,
Table 3 presents the configural model of the four-factor
model with one item-error covariance revealed χ2/df = 1.81
and RMSEA= 0.06, which indicated an acceptable fit across
the IBS-subtype groups. The difference in χ2 between
Models 1 and 2 was not statistically significant (Δχ2 = 38.57,
Δdf = 36, p = 0.354), indicating that factor loadings were
invariant across the groups. The χ2 differences between
Models 2 and 3 (Δχ2 = 32.24, Δdf = 30, p = 0.357), and be-
tween Models 3 and 4 (Δχ2 = 58.95, Δdf = 51, p = 0.207)
were also not significant. Therefore, the factor structure of
the IBS-HR-QOL was invariant across the IBS-subtype
groups.
Criterion validity
As hypothesized, the IBS-HR-QOL was moderately corre-
lated with the following four subscales of the SF-36: role
physical (r = 0.41, p < 0.001), bodily pain (r= 0.41, p <
0.001), social functioning (r= 0.49, p < 0.001), and role emo-
tional (r = 0.47, p < 0.001), and more weakly correlated with
mental health (r = 0.36, p < 0.001), vitality (r = 0.29, p <
0.001), general health (r = 0.25, p < 0.001), and physical
functioning (r = 0.25, p < 0.001).
Known-groups validity
The IBS-HR-QOL scores for mild, moderate, and severe
symptom severities were 2.97 ± 0.70, 2.22 ± 0.83, and
1.81 ± 0.94, respectively (Table 4). The mean differences
overall were significant (F = 41.79, p < 0.001, 2 = 0.24).
A post-hoc inquiry revealed that the mean IBS-HR-QOL
scores were higher in the mild symptom group than in
the moderate and severe symptom groups at p < 0.001.
Convergent validity
As the predefined hypothesis, the IBS-HR-QOL score was
correlated with the anxiety and depression subscales of the
HADS, but the magnitudes of the correlations were only
moderate (r=–0.43, p < 0.001) and small (r =–0.30, p <
0.001), respectively.
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Table 2 Factor loadings
No. Abbreviated item Factor 1 Factor 2 Factor 3 Factor 4 h2
1 Abdominal bloating 0.78 0.22 0.10 0.14 0.69
2 Tenesmus 0.74 0.21 –0.00 0.12 0.61
3 Changed stool form 0.68 0.16 0.37 0.12 0.65
4 Changed stool frequency 0.69 0.03 0.39 0.15 0.65
5 Flatulence 0.73 0.22 0.16 0.22 0.66
6 Depression 0.24 0.77 0.12 0.27 0.73
7 Irritation 0.34 0.69 0.25 0.27 0.73
8 Angry 0.09 0.81 0.18 0.14 0.71
9 Nervousness 0.26 0.77 0.20 0.26 0.76
10 Finding a toilet 0.20 0.32 0.77 0.25 0.70
11 Holding back defecation 0.20 0.10 0.89 0.18 0.75
12 Unpredictability 0.21 0.26 0.80 0.21 0.84
13 Eating before going out 0.24 0.22 0.46 0.63 0.74
14 Consideration of foods 0.20 0.23 0.15 0.80 0.80
15 Favorite foods 0.16 0.21 0.09 0.87 0.86
16 Eating out 0.15 0.28 0.35 0.72 0.79
Bartlett’s sphericity: χ2 = 2676.64, p < 0.001, KMO = 0.90
Factor 1, bowel function; Factor 2, emotions; Factor 3, concerns about social activity; Factor 4, consideration of foods; h2, communality of the measured variables
Bold values: meaningful loadings
Original full version: see additional file 1
Fig. 1 Confirmatory factor analysis for the IBS-HR-QOL. Factor 1, bowel function; Factor 2, emotions; Factor 3, concerns about social activity; Factor
4, consideration of foods; e, error term
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Internal consistency reliability
The corrected item-total correlations for all items ranged
from 0.50 to 0.70. Cronbach’s alpha value of the total IBS-
HR-QOL was 0.93, which met the threshold criterion
range of 0.70–0.95. Cronbach’s alpha of each subscale
ranged from 0.85 to 0.90 (Table 5).
Test–retest reliability
The ICC of the total IBS-HR-QOL was 0.88 (confidence
interval = 0.79–0.86, p < 0.001), while those of subscales 1 to
4 were 0.81 (confidence interval = 0.68–0.88, p < 0.001), 0.82
(confidence interval = 0.69–0.89, p < 0.001), 0.88 (confidence
interval = 0.79–0.92, p < 0.001), and 0.77 (confidence inter-
val = 0.79–0.92, p < 0.001), respectively (Table 5). Therefore,
the temporal stability of the total and subscales was
demonstrated.
Discussion
The IBS-HR-QOL, which was developed and evaluated
in this study, comprises a total of 16 items. This instru-
ment consists of four subscales: bowel function, emo-
tions, concerns about social activity, and consideration
of foods. In this study, the four subscales were clustered
by EFA and supported by CFA. To the best of our know-
ledge, this is the second study that has applied both EFA
and CFA to test the structural validity of an IBS-specific
HRQOL instrument. The first such study was conducted
by Andrae et al. [34] with the IBS-QOL [9] in diarrhea-
predominant IBS patients. And, the authors suggested
that the IBS-QOL [9] was one dimensional in the
diarrhea-predominant patients. However, the single di-
mension is inconsistent with the conceptual background
of the original IBS-QOL instrument [9], and with the
worldwide consensus of the multidimensionality of
HRQOL [4]. To establish whether or not the underlying
structure of the IBS-QOL in diarrhea-predominant IBS
patients varied in comparison with that in other sub-
types of IBS patients, it would be more appropriate to
apply MGCFA [29]. From that perspective, MGCFA was
used in the present study as an ancillary analytical tool,
and demonstrated that the four-factor structural model
of the IBS-HR-QOL was equivalent across the IBS-
subtype groups. In other words, the IBS-HR-QOL may
be used regardless of the patient’s IBS subtype. However,
it should be noted that the present sample was too small
to enable an unequivocal interpretation of the MGCFA
findings. Thus, further study is required with sufficiently
large samples to enable a robust MGCFA across the IBS
subtypes.
Criterion validity is the degree to which the measurement
instrument is an adequate reflection of a gold standard, and
is satisfied if the correlation with the gold standard is at
least 0.7 [27]. The SF-36 is generally accepted as a gold-
standard measure of HRQOL in IBS research [35].
Table 3 Tests for multigroup invariance across the IBS-subtype groups
χ2 (df ) χ2/df RMSEA (90 % CI) Comparison Δχ2 (Δdf ) p
Model 1a 704.92 (388) 1.81 0.06 (0.05–0.06) - - -
Model 2b 743.48 (424) 1.75 0.05 (0.05–0.06) Model 1 vs. Model 2 38.57 (36) 0.354
Model 3c 775.72 (454) 1.71 0.05 (0.04–0.06) Model 2 vs. Model 3 32.24 (30) 0.357
Model 4d 834.67 (505) 1.65 0.05 (0.04–0.06) Model 3 vs. Model 4 58.95 (51) 0.207
aConfigural Model: No equality constraints imposed
bAll factor loadings constrained equal
cAll factor loadings and covariances among 4 factors constrained equal
dAll factor loadings, covariances among 4 factors, and error variance constrained equal
Δχ2= difference in χ2 values between models
Δdf = difference in number of degrees of freedom between models
Table 4 Known-groups validity according to IBS severity classification
Classification of IBS severity F Post-hoc test Effect
size
(η2)Mild Moderate Severe
(n = 101) (n = 115) (n = 45)
Mean ± SD Mean ± SD Mean ± SD
Total 2.97 ± 0.70 2.22 ± 0.83 1.81 ± 0.90 41.79a* Mild>Moderate, Severeb 0.24
F1 2.42 ± 0.90 1.57 ± 0.94 1.22 ± 0.97 34.49* Mild>Moderate>Severec 0.21
F2 3.11 ± 0.80 2.28 ± 1.00 1.71 ± 0.94 46.84a* Mild>Moderate, Severeb 0.25
F3 3.14 ± 1.03 2.49 ± 1.27 2.15 ± 1.31 14.22a* Mild>Moderate, Severeb 0.10
F4 3.20 ± 0.83 2.54 ± 1.13 2.17 ± 1.16 21.04a* Mild>Moderate>Severeb 0.13
Factor 1, bowel function; Factor 2, emotions; Factor 3, concerns about social activity; Factor 4, consideration of foods
aWelch test; bGames-Howell test; cScheffé’s test
*p < 0.001
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However, the SF-36 is a generic HRQOL instrument, and
its likelihood of accurately measuring clinically important
changes is lower than that of a disease-specific HRQOL in-
strument [7]. Even so, the SF-36 and disease-specific
HRQOL instruments measure some common attri-
butes. Therefore, the cutoff correlation value for the
criterion validity between the SF-36 and IBS-specific in-
struments was considered to be ≥0.4 [11], which is
lower than that generally used (>0.70). In the present
study, the IBS-HR-QOL was correlated with four sub-
scales of the SF-36 (role physical, social functioning,
role emotional, and bodily pain) at >0.4. These findings
are similar to those of validity testing of the IBS-36 [11]
and IBS-QOL [9] relative to the SF-36.
Known-groups validity is associated with expected dif-
ferences between subgroups of patients [36]. In the
present study, the overall IBS-HR-QOL and all of its
subscales satisfied the known-groups validity with the
IBS-SSS classification. The effect sizes of the group dif-
ferences for the overall IBS-HR-QOL were moderate
based on Cohen’s criteria [37] for small (0.10), moderate
(0.25), and large (0.40) effects. However, those of two
subscales (“concerns about social activity” and “consider-
ation of foods”) were small, requiring considerable
interpretation.
Convergent validity refers to the extent to which a new
scale is correlated with a well-established related measure
according to a priori expectations [36]. The present study
demonstrated that the IBS-HR-QOL satisfied the construct
validity of a moderate correlation with the anxiety subscale
of the HADS, as predicted by the study hypothesis. How-
ever, there was a weak correlation between IBS-HR-QOL
and the depression subscale. This weaker correlation of the
depression subscale compared with the anxiety subscale
was also noted in the validity test of IBS-IS with HADS
[12]. In line with this finding, it is recommended that in
practice, anxiety rather than depression should be managed
as one way of improving the HRQOL of IBS patients [38].
Internal consistency reliability refers to the extent to
which items are homogeneous, and thus measure the
same construct [27]. Existing HRQOL instruments for
IBS patients presented a Cronbach’s alpha value that is
either too high (>0.95), implying the redundancy of one
or more items [34, 39], or too low (<0.70), inferring a
lack of homogeneity among items [8]. In the present
study, Cronbach’s alpha values for all of the IBS-HR-QOL
total and subscales satisfied the criterion of 0.75–0.95,
thus exhibiting excellent internal consistency reliability.
Test–retest reliability establishes the presence of tem-
poral stability by repeated measurement in the same sub-
jects [4]. The ICC and Pearson’s correlation coefficient are
commonly used as parameters for measuring test–retest re-
liability. However, Pearson’s correlation coefficient does not
take into account systematic differences between repeated
measures, and the ICC is thus recommended as a more ap-
propriate parameter [36]. The ICC was therefore used in
the present study, and demonstrated satisfactory temporal
stability of the IBS-HR-QOL over a 1-week period. Simi-
larly, 1- or 2-week intervals were used in other studies in-
volving the IBS-QOL [9, 23, 39, 40] and IBS-36 [11], in
which their temporal stability was also satisfied. It may
therefore be assumed that the attributes of HRQOL in IBS
patients are stable for 1–2 weeks.
The IBS-HR-QOL developed in this study exhibited ex-
cellent psychometric properties. This instrument has prac-
tical strengths. First, there were few missing values for the
IBS-HR-QOL items in the present study, which implies
that this instrument is comprehensible to IBS patients.
Second, this instrument, which comprises a total of 16
items, is shorter than other instruments: the IBSQOL,
IBS-QOL, IBS-HRQOL, IBS-36, and IBS-IS comprise 30,
34, 26, 36, and 26 items, respectively. It can be assumed,
therefore, that the IBS-HR-QOL may represent a lesser
burden for patients, rendering it more feasible for use in
clinical practice and research than these other instru-
ments. However, there are some limitations when applying
the IBS-HR-QOL. The first limitation is that no test of re-
sponsiveness was conducted to determine the ability of
the IBS-HR-QOL to detect important clinical changes
over time [27]. A longitudinal study is thus recommended
to measuring the changes in HRQOL between before and
after a therapeutic intervention for IBS patients. The sec-
ond limitation is that the IBS-HR-QOL has been devel-
oped using a paper-and-pencil mode of administration. In
a busy clinical practice, this mode of application can be a
burden for health professionals in terms of requiring the
dissemination, collection, and calculation of paper-based
answers [41]. As an alternative, it is recommended for a
future study to transform the present IBS-HR-QOL into a
computer-mode instrument (e.g., utilizing a laptop or
handheld computer).
Conclusion
The IBS-HR-QOL comprises 4 subscales (bowel function,
emotions, concerns about social activity, and consider-
ation of foods) with a total of 16 items. The IBS-HR-QOL
Table 5 Internal consistency reliability and test-retest reliability
Cronbach’s
alpha
ICC (95 % confidence
interval)
Total IBS-HR-QOL 0.93 0.88 (0.79–0.86)*
Factor 1: Bowel function 0.85 0.81 (0.68–0.88)*
Factor 2: Emotions 0.87 0.82 (0.69–0.89)*
Factor 3: Concerns about social
activity
0.90 0.88 (0.79–0.92)*
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demonstrated good psychometric properties: content valid-
ity, factorial validity, criterion validity, known-groups valid-
ity, convergent validity, internal consistency reliability, and
test–retest validity. The IBS-HR-QOL is easily comprehen-
sible to patients, and shorter than similar instruments. It is
therefore feasible for use in clinical practice and research.
Further studies are needed to determine the responsiveness
of the IBS-HR-QOL.
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